[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/12, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 한미약품, 근육보존 '마이오스타틴 저해제' 다른 이유? 
[https://www.biospectator.com/news/view/30377](https://www.biospectator.com/news/view/30377)

 프로바이오, 동아 앱티스와 '이중타깃 ADC' 항체 딜  
[https://www.biospectator.com/news/view/30352](https://www.biospectator.com/news/view/30352)

 셀트리온, '코센틱스 시밀러' 호주 시판허가 신청
[https://www.biospectator.com/news/view/30384](https://www.biospectator.com/news/view/30384)

 펩젠, ‘펩타이드-ASO 접합체’ DM1 2상 “교정률 최대"
[https://www.biospectator.com/news/view/30372](https://www.biospectator.com/news/view/30372)

 대웅, 이노보 ‘PGE2 분해효소 저해제’ 국내1상 "승인" 
[https://www.biospectator.com/news/view/30379](https://www.biospectator.com/news/view/30379)

 셀트리온제약, KCGS ESG 평가서 "통합 A등급 획득"
[https://www.biospectator.com/news/view/30383](https://www.biospectator.com/news/view/30383)

 삼진제약, 경구용 항응고제 ‘렉사반정' 15·30·60mg 출시
[https://www.biospectator.com/news/view/30388](https://www.biospectator.com/news/view/30388)

 빔, '염기편집 세포치료제’ 겸상적혈구증 1/2상 “성공" 
[https://www.biospectator.com/news/view/30369](https://www.biospectator.com/news/view/30369)

 루닛, 3Q 매출 222억 "전년比 13% 증가" 
[https://www.biospectator.com/news/view/30390](https://www.biospectator.com/news/view/30390)

 HLB제약, 화성시 '향남 신공장' 기공식 개최
[https://www.biospectator.com/news/view/30389](https://www.biospectator.com/news/view/30389)

 넥스아이, 코스닥 상장 첫날 "주가 39% 하락"
[https://www.biospectator.com/news/view/30391](https://www.biospectator.com/news/view/30391)

 휴온스, 3분기 매출 1440억 "전년比 6.3% 감소"
[https://www.biospectator.com/news/view/30393](https://www.biospectator.com/news/view/30393)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/12, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)